Resona Asset Management Co. Ltd. Invests $26.51 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Resona Asset Management Co. Ltd. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 37,211 shares of the biopharmaceutical company’s stock, valued at approximately $26,507,000.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Geode Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after purchasing an additional 155,369 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Regeneron Pharmaceuticals by 7.9% during the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock worth $1,456,864,000 after acquiring an additional 149,124 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in Regeneron Pharmaceuticals by 33.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after acquiring an additional 393,997 shares during the period. Amundi increased its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $802,036,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on REGN. Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research note on Monday, March 31st. TD Cowen cut their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Sanford C. Bernstein decreased their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Stock Down 6.1 %

Shares of REGN opened at $573.45 on Friday. The firm has a 50 day simple moving average of $676.70 and a two-hundred day simple moving average of $779.13. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a one year low of $572.00 and a one year high of $1,211.20. The company has a market cap of $62.69 billion, a P/E ratio of 14.98, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $11.86 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.61%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.